drugset
drugset / Trial / NCT00002571

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

NCT00002571 ↗

Phase 2 Completed 52 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Antiviral therapy may be effective treatment for AIDS-related lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and antiviral therapy in treating patients who have AIDS-related lymphoma.

Timeline

Start
1994-06
Primary completion
2003-11
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown 5 unknown Intravenous
Subject Cyclophosphamide Other / unclassified 490 mg/m2 Intravenous
Subject Cytarabine Small molecule 30 mg/m2 Intravenous
Subject Cytarabine Small molecule 225 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 19 mg/m2 Intravenous
Subject Etoposide Small molecule 90 mg/m2 Intravenous
Subject Methotrexate Small molecule 12 mg Intravenous
Subject Methotrexate Small molecule 90 mg/m2 Intravenous
Subject Prednisone Other / unclassified 60 mg/m2 Oral
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous
Subject filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Background Leucovorin Small molecule 25 mg/m2 Oral
Background trimethoprim-sulfamethoxazole Unknown 1 unknown Oral

Indications

lymphoma